Evommune, Inc.
EVMNStock
$11.71
Market Cap$431.86M
P/E—
Div yield—
Beta-0.46
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-34.11%
Price vs S&P 500 (4W)-42.07%
VGM Score49.49
Market Capitalization$431.86M
Earnings Surprise History
Q1 26-0.64est. -0.76
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.33
4.31
4.35
4.12
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EVMNEvommune, Inc. | — | A | F | $11.71 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Evommune Inc is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, including chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's pipeline features two lead candidates, EVO756 and EVO301, currently in clinical development.